Michelle

About

Michelle Lynn Hall has spent two decades at the forefront of biotech, from her early work in computational chemistry and small molecules at Schrödinger and Novartis, to her leadership in mRNA, lipid nanoparticles, and genetic medicines at Moderna and Eli Lilly. She founded and scaled Lilly’s Genetic Medicines group in Boston, building collaborations across China and Europe, and has held leadership roles in research and development. Michelle holds a Ph.D. in theoretical chemistry from Columbia University and has served as an advisor, entrepreneur, and board member in the biotech venture ecosystem.

Source (opens in a new tab)